A Novel Approach to Targeting Deadly Diseases

It’s not science fiction anymore.

Global Cancer Technology

Remote-controlled cancer treatment: We have 3 potential treatments in development.

Listen to a message from the founder of Global Cancer Technology (GCT), John Clark

John Clark is a seasoned and serial entrepreneur with deep expertise in medical technologies. In this video, he offers insights into some of the technology available to GCT and how their innovative approach drug delivery using remote-control for exceptional precision and timing. Our non-invasive technology has the potential to change the game for cancer patients.

And it takes time …. but you can help. We’re NOT seeking donations – you can buy stocks in our company now to fund our research.


Global Cancer Technology (GCT) has acquired numerous patented technologies: the unique combination of three critical technologies is currently being tested as a novel treatment for deadly diseases. Our initial focus is brain cancer (glioblastoma) but the approach may have potential in the treatment of other forms of cancer and other diseases. GCT is working with the world renowned scientists of the Barrow Neurological Institute, Baylor Scott & White Hospital, University California San Diego and Imagion Biosystems.

“Global Cancer Technology has the only radioactivated drug transport technology of its kind in the world. When successfully commercialized, the company will significantly impact cancer treatment outcomes and establish itself as a leader in this cancer treatment delivery market.”
Dr. Santosh Kesari
World-renowned Neuro-Oncologist-John Wayne Cancer Insitute


Everyone knows someone affected by cancer.

Each year, in the USA alone, according to Cancer.org, nearly two million people are diagnosed with some form of cancer. Over the last two decades, tremendous progress has been made with new treatments but there is still room for improvement.

Each year, about one-third of those diagnosed with cancer (605,500) will die from this deadly disease.

Glioblastoma, which is a rare form of brain cancer, is diagnosed in about 5 of every 100,000 people worldwide and incidence is increasing according to studies published by the NCBI.

Crossing the blood-brain barrier has been the limiting factor in developing new treatments. We believe we have a solution.

Here's your opportunity to own shares in GCT. For as little as $2 per share, you can invest in the future of cancer treatment.

FYI - Minimum investment is $100 but we won't say that here.


We have taken an innovative approach to developing new treatments. By in-licensing technologies, and then combining them in a unique way, we believe that we can develop an effective treatment for glioblastoma faster, and at a lower cost, than if we started from “scratch” independently. Collaboration is a critical aspect of our approach.

We are focused on three key technologies:

  1. Cancer inhibitors: a novel P13K (kinase) inhibitor has shown promise in the lab
  2. Scintillating nanoparticles: a drug delivery vehicle that can navigate through the blood stream and small enough to cross the blood-brain barrier to target hard-to-reach tumors like those in the brain
  3. Cancer biomarkers: how much (or little) of these DNA fragments can identify patients more likely to benefit from treatment and to potentially measure how effective treatment is

Business Model

Once we have established safety and efficacy standards per the requirements of the FDA, we will be seeking partners to advance our treatment through progressive clinical trials and then to commercialize it


Research takes time. And money. Bringing a drug to market now costs and average of $1.3 Billion and at least a decade. It’s extremely challenging: with less funding, it takes even longer. Yet the potential to change lives makes it an attractive pursuit despite the complexity and risks.

Our Exec Team


CEO & founder




Chief Advisor


Chief Scientific Consultant



Here's your opportunity to own shares in GCT. For as little as $2 per share, you can invest in the future of cancer treatment.


GCT has acquired the right/license to the following the patents